A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkins Lymphoma and CD30-expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Therapy
Principal Investigator
Dipti Patel-Donnelly, MDLocations
Fairfax Office
Gainesville Office
Arlington Office
Alexandria Office
Learn More About This Trial
Other Relevant Trials
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Principal Investigator
Mitul Gandhi, MDA Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)